Biowaiver as a Bioequivalence Study Option

SCIENTIFIC RELEVANCE. Biowaiver is a procedure for establishing the bioequivalence of generic and reference products without in vivo studies. Regulatory requirements for this procedure, as described in a variety of documents, differ in certain features and aspects. These differences need to be analysed.

AIM. The aim was to compare international and Russian regulatory approaches to the Biopharmaceutics Classification System-based biowaivers, provide recommendations on comparative dissolution testing, and outline opportunities for streamlining the regulatory framework of the Eurasian Economic Union (EAEU).

DISCUSSION. In this article, the authors analyse biowaiver requirements and describe procedures for assessing the permeability and pH-dependent solubility of medicines, comparing dissolution profiles in various media that simulate the gastrointestinal environment, and interpreting test results. This paper shows the role of excipients in the solubility and permeability of an active substance.

CONCLUSIONS. The authors recommend a methodological approach to the biowaiver procedure for replacing in vivo bioequivalence studies with in vitro tests under the current EAEU regulatory framework and list the characteristics of medicines that limit the applicability of the procedure. In conclusion, this article provides a rationale for harmonising the existing guidelines and requirements.

1. Mishra V, Gupta U, Jain NK. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies. Pharmazie. 2010;65(3):155–61. https://doi.org/10.1691/ph.2010.9231

2. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. https://doi.org/10.1023/A:1016212804288

3. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J Pharm Sci. 2007;96(3):522–31. https://doi.org/10.1002/jps.20765

4. Ramenskaya GV, Shohin IE, Kulinich JI. Biopharmaceutical classifications of active pharmaceutical ingredients: BCS and BDDCS. Bulletin of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2012;(1):212–5 (In Russ.). EDN: OZCXTL

5. Bocci G, Oprea TI, Benet LZ. State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references. AAPS J. 2022;24(2):37. https://doi.org/10.1208/s12248-022-00687-0

6. Celso V, Accennato VC, Costa F, Teixeira LS, Abreu F, Mundim IM, et al. Bioequivalence between two tablets of lacosamide in healthy subjects under fasting condition. Int Ann Med. 2018;12(6). https://doi.org/10.24087/IAM.2018.2.6.556

7. Swarnkar G, Joshi P, Shah J, Soni N, Anju G. Solubility determination of lacosamide by HPLC with application to the biopharmaceutics classification system. IJPE. 2011;1(1):51–71.

8. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci. 2009;98(4):1206–19. https://doi.org/10.1002/jps.21525

9. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121–31. https://doi.org/10.1002/jps.20444

10. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004;93(8):1945–56. https://doi.org/10.1002/jps.20131

11. Atiyah Altameemi KK, Abd-Alhammid SN. Anastrozole nanoparticles for transdermal delivery through microneedles: preparation and evaluation. J Pharm Negat Results. 2022;13(3):974–80. https://doi.org/10.47750/pnr.2022.13.03.152

12. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci. 2006;95(5):974–84. https://doi.org/10.1002/jps.20614

13. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Islambulchilar Z. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug Dev Ind Pharm. 2009;35(12):1496–502. https://doi.org/10.3109/03639040903037199

14. Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, et al. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J Pharm Sci. 2011;100(1):22–33. https://doi.org/10.1002/jps.22259

15. Smekhova IE, Petrova YuM, Kondratieva IA, Rodygina AN, Turetskova NN. Dissolution test and modern approaches to assessing the equivalence of medicinal products (review). Drug Development and Registration. 2013;(1):50–61 (In Russ.). EDN: QZRXPN

16. Shamal LL, Yarushok TA, Shokhin IE, Ramenskaya GV. Equivalence study of biopharmaceutical solubility of drug substances used in the treatment of oncological diseases. Remedium. 2014;(11):73–6 (In Russ.). EDN: TAKAAZ

17. Grebenkin DYu, Stanishevskiy YM, Shohin IE. Modern approaches of dissolution profile test (review). Drug Development and Registration. 2016;(1):166–71 (In Russ.). EDN: WBODJF

18. Ramenskaya GV, Shohin IE, Savchenko AYu, Kulinich YuI, Davydova KS. Biowaiver procedure: current approaches and general guidelines for evaluating the in vitro equivalence of immediate release drugs. Recipe. 2010;(5):33–9 (In Russ.). EDN: OIUTUD

19. Shokhin IE, Ramenskaya GV, Vasilenko GF, Malashenko EA. Assessment of the possibility of using comparative in vitro dissolution kinetics (biowaiver) instead of in vivo bioequivalence evaluation for establishing the interchangeability of generic drugs. Pharm Chem J. 2011;45(2):107–9. https://doi.org/10.1007/s11094-011-0570-6

20. Shohin IE, Ramenskaya GV, Yarushok TA, Zimakova EA, Vasilenko GF, Davydova KS. Biowaiver procedure for vitamins on the example of folic acid generics. Bulletin of Roszdravnadzor. 2011;(1):67–71 (In Russ.). EDN: QCIMOH

21. Singh GN, Gupta RP. Adsorption characteristics of norfloxacin to pharmaceutical additives. Drug Dev Ind Pharm. 1988;14(13):1845–54. https://doi.org/10.3109/03639048809151991

22. Thapa P, Paudel B. In vitro interactions of ciprofloxacin with selected drugs and excipients. KUSET. 2013;(9):1–14.

23. Bochkov PO, Kolyvanov GB, Litvin AA, Zherdev VP, Shevchenko RV. Effects of the high-molecular excipients on optimization of the pharmacokinetic properties of drugs. Pharmacokinetics and Pharmacodynamics. 2016;(1):3–11 (In Russ.). EDN: WGCBSZ

24. Druzhininskaya OV, Smekhova IE. Dissolution media used in development and quality control of drugs. Drug Development and Registration. 2017;(3):144–50 (In Russ.). EDN: ZRQDRL

25. Kotsur JuM, Flisyuk EV, Narcevich IA. Development of enteric-coated tablets of sodium 4,4’-(propnadiamido)dibenzoate. Drug Development and Registration. 2022;11(2):109– 17 (In Russ.). https://doi.org/10.33380/2305-2066-2022-11-2-109-117

26. Naylor T, Connolly PC, Martini IG, Elder DP, Minekus M, Havenaar R, et al. Use of a Gastro-Intestinal Model and GastroPLUS™ for the prediction of in vivo performance. Industrial Pharm. 2006;12:9–12.

27. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci. 2002;17(4–5):183–93. https://doi.org/10.1016/s0928-0987(02)00185-9

28. Shohin IE, Ramenskaya GV. Methods of forecasting the intestinal permeability of medicinal substances with the use of computer simulation. Biomedicine. 2011;(2):35–40 (In Russ.). EDN: NVYEGB

29. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(1):41–67. https://doi.org/10.1016/s0169-409x(01)00179-x

30. Gigante V, Pauletti GM, Kopp S, Xu M, Gonzalez-Alvarez I, Merino V, et al. Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET DMPK. 2020;9(1):23–39. https://doi.org/10.5599/admet.850

31. van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1(2):175–85. https://doi.org/10.1517/17425255.1.2.175

32. Pyatigorskaya NV, Kravchenko AD. Caco-2 intestinal permeability study of phenyltetrahydroquinolinedione derivative—TRPA₁ antagonist. Drug Development and Registration. 2022;11(3):195–201 (In Russ.). https://doi.org/10.33380/2305-2066-2022-11-3-195-201

33. Grebenkin DYu, Stanishevskiy YM, Shohin IE, Stoinova AM, Karpova MA, Koryakova AG, et al. Сасо-2 intestinal permeability and Pgp-affinity of phosphazide. Drug Development and Registration. 2017;(4):238–42 (In Russ.). EDN: ZTWVHZ

34. Shohin IE, Kulinich YuI, Ramenskaya GV, Kukes VG. Application of a biological model for the assessment of intestinal permeability in vitro — a monolayer of Caco-2 epithelial cells. Biomedicine. 2012;(3):91–7 (In Russ.). EDN: PGJLRV

35. Gorbunova EV, Goryachev DV, Gorskaya TE, Bogdanov AN. Current approaches to demonstration of therapeutic equivalence of locally-acting gastrointestinal drugs. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2021;11(4):228–38 (In Russ.). https://doi.org/10.30895/1991-2919-2021-11-4-228-238

36. Menshikova LA, Lvova AA, Shohin IE, Boldina YuE, Komarov TN, Medvedev YuV. Validation of UV-spectrometry assay method for dissolution profile test for moxifloxacine tablets. Drug Development and Registration. 2016;(2):94– 7 (In Russ.). EDN: WYJZKT

37. Yoshida H, Shibata H, Izutsu KI, Goda Y. Comparison of dissolution similarity assessment methods for products with large variations: f2 statistics and model-independent multivariate confidence region procedure for dissolution profiles of multiple oral products. Biol Pharm Bull. 2017;40(5):722–5. https://doi.org/10.1248/bpb.b16-00904

38. Shohin IE, Bagaeva NS, Malashenko EA, Kuzina VN. Method of estimating the equivalence of dissolution profiles: a modern view (review). Drug Development and Registration. 2020;9(2):145–50 (In Russ.). https://doi.org/10.33380/2305-2066-2020-9-2-145-150

39. Setkina SB, Khishova OM, Zubkevich LV, Kaplin AV, Kaplina EV. Impact of the biopharmaceutical factors on the in vitro equivalence of clopidogrel containing generic medicines. Bulletin of Pharmacy. 2014;(1):33–8 (In Russ.). EDN: SEZJSP